Aliskiren attenuates chronic carbon tetrachloride-induced liver injury in mice

European Journal of Clinical Investigation

Volumn 42, Issue 12, 2012, Pages 1261-1271

  Lee, Kuei Chuan ^a,b   Chan, Che Chang ^a,b   Yang, Ying Ying ^a,b   Hsieh, Yun Cheng ^a,b   Huang, Yi Hsiang ^a,b   Lin, Han Chieh ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Angiotensin II; Direct renin inhibitor; Liver fibrosis; Liver injury

Indexed keywords

ALISKIREN; ANGIOTENSIN II; CARBON TETRACHLORIDE; PROTEIN P47; RECEPTOR; RENIN; RENIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; DOWN REGULATION; HEPATITIS; KUPFFER CELL; LIPID PEROXIDATION; LIVER CELL; LIVER FIBROSIS; LIVER INJURY; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STELLATE CELL; TREATMENT DURATION;

AMIDES; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARBON TETRACHLORIDE; DRUG INTERACTIONS; DRUG-INDUCED LIVER INJURY, CHRONIC; FUMARATES; LIVER; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED C57BL; RANDOM ALLOCATION; RENIN;

EID: 84869872751     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2012.02725.x     Document Type: Article

References (40)

1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18.
2. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-69.
3. Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, Angus PW. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 2002;123:1667-76.
4. Yang YY, Lin HC, Huang YT, Lee TY, Hou MC, Lee FY et al. Effect of 1-week losartan administration on bile duct-ligated cirrhotic rats with portal hypertension. J Hepatol 2002;36:600-6.
5. Herath CB, Warner FJ, Lubel JS, Dean RG, Jia Z, Lew RA et al. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol 2007;47:387-95.
6. Lubel JS, Herath CB, Burrell LM, Angus PW. Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. J Gastroenterol Hepatol 2008;23:1327-38.
7. Bataller R, Gabele E, Parsons CJ, Morris T, Yang L, Schoonhoven R et al. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 2005;41:1046-55.
8. Bataller R, Gabele E, Schoonhoven R, Morris T, Lehnert M, Yang L et al. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol 2003;285:G642-51.
9. Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000;118:1149-56.
10. Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003;112:1383-94.
11. Gradman AH, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol 2008;51:519-28.
12. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308:698-705.
13. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002;39:E1-8.
14. Fisher ND, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008;117:3199-205.
15. Sakaida I, Terai S, Yamamoto N, Aoyama K, Ishikawa T, Nishina H et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 2004;40:1304-11.
16. Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet 2008;47:515-31.
17. Lu H, Rateri DL, Feldman DL, Fukamizu A, Ishida J et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008;118:984-93.
18. Yamamoto E, Kataoka K, Dong YF, Nakamura T, Fukuda M, Tokutomi Y et al. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension 2009;54:633-8.
19. Rodriguez-Sargent C, Cangiano JL, Martinez-Maldonado M. Circadian rhythms of plasma renin levels in the anesthetized rat. Ren Physiol 1982;5:53-6.
20. Yang L, Chan CC, Kwon OS, Liu S, McGhee J, Stimpson SA et al. Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2006;291:G902-11.
21. Chang CC, Lee WS, Huang HC, Lee FY, Wang SS, Lin HC et al. Aliskiren reduces portal pressure in portal hypertensive rats. Eur J Clin Invest 2012;42:526-33.
22. Chang CC, Huang HC, Lee WS, Wang SS, Lee FY, Lin HC et al. Aliskiren reduces portal pressure in cirrhotic rats. Liver Int 2012;32:692-3.
23. McMurray JJ, Abraham WT, Dickstein K, Kober L, Massie BM, Krum H. Aliskiren, Altitude, and the implications for Atmosphere. Eur J Heart Fail 2012;14:341-3.
24. Reinehr R, Becker S, Keitel V, Eberle A, Grether-Beck S, Haussinger D. Bile salt-induced apoptosis involves NADPH oxidase isoform activation. Gastroenterology 2005;129:2009-31.
25. Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury: present concepts. J Gastroenterol Hepatol 2011;26(Suppl 1):173-9.
26. Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores GJ. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003;83:655-63.
27. Canbay A, Feldstein AE, Higuchi H, Werneburg N, Grambihler A, Bronk SF et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003;38:1188-98.
28. Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int 2006;26:1175-86.
29. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003;114:181-90.
30. Leung PS, Suen PM, Ip SP, Yip CK, Chen G, Lai PB. Expression and localization of AT1 receptors in hepatic Kupffer cells: its potential role in regulating a fibrogenic response. Regul Pept 2003;116:61-9.
31. Bataller R, Sancho-Bru P, Gines P, Lora JM, Al-Garawi A, Sole M et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003;125:117-25.
32. Roth S, Michel K, Gressner AM. (Latent) transforming growth factor beta in liver parenchymal cells, its injury-dependent release, and paracrine effects on rat hepatic stellate cells. Hepatology 1998;27:1003-12.
33. Kossmann T, Manthey CL, Brandes ME, Morganti-Kossmann MC, Ohura K, Allen JB et al. Kupffer cells express type I TGF-beta receptors, migrate to TGF-beta and participate in streptococcal cell wall induced hepatic granuloma formation. Growth Factors 1992;7:73-83.
34. Iredale JP, Benyon RC, Arthur MJ, Ferris WF, Alcolado R, Winwood PJ et al. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology 1996;24:176-84.
35. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Yanase K et al. Angiotensin-II induces the tissue inhibitor of metalloproteinases-1 through the protein kinase-C signaling pathway in rat liver fibrosis development. Hepatol Res 2003;27:51-6.
36. Krop M, Garrelds IM, de Bruin RJ, van Gool JM, Fisher ND, Hollenberg NK et al. Aliskiren accumulates in Renin secretory granules and binds plasma prorenin. Hypertension 2008;52:1076-83.
37. Danser AH. The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor? Hypertens Res 2010;33:4-10.
38. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-27.
39. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, Kvakan H et al. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008;51:682-8.
40. Nguyen G, Muller DN. The biology of the (pro)renin receptor. J Am Soc Nephrol 2010;21:18-23.